An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms IMPRES Extn
- Sponsors Novartis Pharmaceuticals Corporation
- 27 Jun 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
- 25 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 11 May 2014 New trial record